|
KMID : 1141720200080020075
|
|
폐쇄성폐질환
2020 Volume.8 No. 2 p.75 ~ p.79
|
|
|
Anti-inflammatory Reliever in Asthma Management
|
|
Kim Su-Jeong
|
|
|
Abstract
|
|
|
|
Asthma is a chronic airway inflammatory disease, characterized by variable respiratory symptoms and airflow limitation. Patients with asthma can experience episodic flare-ups and all patients with asthma are at risk of exacerbations, even if they have few symptoms. Medications used in asthma treatment are categorized as reliever medications act to rapidly reduce airflow obstruction, and controller medications regulate airway inflammation. Short-acting beta2-agonists (SABAs) are highly effective reliever of asthma symptoms but, SABA-only treatment increases the risk of severe exacerbations and asthma-related death. The updated Global Initiative for Asthma (GINA) no longer recommends treatment with SABA alone but highlights the use of anti-inflammatory reliever with combination inhaled corticosteroid (ICS)-formoterol in adults and adolescents to control their underlying inflammation and also for symptom relief. ICS-formoterol as an anti-inflammatory reliever reduces severe exacerbations across all severities of asthma. In adults and adolescents with mild asthma, treatment with as-needed low dose ICS-formoterol reduced the risk of severe exacerbations by about two-third compared with SABA-only treatment, and is non-inferior to daily low dose ICS. For adults and adolescents with moderate to severe asthma, the ICS-formoterol maintenance and reliever regimen significantly reduced exacerbations and provided similar levels of asthma control at relatively low doses of ICS, compared with a fixed dose of ICS-LABA as maintenance treatment or a higher dose of ICS, both with as-needed SABA. In conclusion, ICS-formoterol as an anti-inflammatory reliever enables fast improvement of breakthrough symptoms, and reducing inflammation which is central to control symptoms and reduce future risks such as exacerbations.
|
|
|
KEYWORD
|
|
|
Asthma, Drug therapy, Combination, Administration, Inhalation, Bronchodilator agents, Glucocorticoids
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|